Business Context and Reporting Period
This Form 6-K filing was submitted by GlaxoSmithKline plc, GlaxoSmithKline Capital plc, and GlaxoSmithKline Capital Inc. on March 13, 2013. The registrants are foreign issuers filing pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The primary purpose of this report is to incorporate by reference a specific exhibit into the registrants' Registration Statement on Form F-3 (File No. 333-172621).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a procedural vehicle to include a "Statement of Computation of Ratio of Earnings to Fixed Charges" (Exhibit 12.1) within a registration statement, rather than a standalone financial results report.
Material Changes
The filing text does not provide data regarding material changes versus prior comparable periods. No comparative financial analysis is included in this specific document.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or contingencies. The document is limited to the incorporation of Exhibit 12.1 into the Form F-3 registration statement.
Investor Verification Checklist
- Verify the contents of Exhibit 12.1 (Statement of Computation of Ratio of Earnings to Fixed Charges) referenced in the Form F-3 Registration Statement (File No. 333-172621).
- Confirm the status of the Form F-3 registration statement to understand the context of the debt or fixed charge computations.
- Review the most recent Form 20-F or quarterly reports for actual revenue, profit, and cash flow figures, as they are absent from this 6-K.